Breathtaking Stock: Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)

On 24 Jan 2020, Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock observed trading -8.00% off 52-week high price. On the other end, the stock has been noted 21.41% away from low price over the last 52-weeks. The stock disclosed a move of 2.78% away from 50 day moving average and 5.77% away from 200 day moving average. Moving closer, we can see that shares have been trading -2.82% off 20-day moving average.

BrainStorm Cell Therapeutics Inc. (BCLI) reported recently financial results for the third quarter ended September 30, 2019 and recent corporate updates.

“On October 11, 2019 we reached a major corporate milestone by fully enrolling 200 patients in the Phase 3 clinical trial of NurOwn® in ALS (Amyotrophic Lateral Sclerosis). Additionally, on October 28, we reported that we received notification from the NurOwn Data Safety Monitoring Board (DSMB) that after reviewing all of the safety data as of September 30, the study should continue without any changes in the protocol. The DSMB indicated they did not identify any important safety concerns,” stated Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics.  He added, “Our Phase 2 trial of NurOwn in Progressive MS (Multiple Sclerosis) continues to enroll patients in several of the leading U.S. medical centers and we anticipate announcing additional investigation-al centers of excellence in the near future. The first eight (8) participants have been enrolled in the study.”

Financial Results for the Three Months Ended September 30, 2019

Cash, cash equivalents, and short-term bank deposits were $2.1M at September 30, 2019, contrast to $2.7M at June 30, 2019.
— Our total accessible funding which includes cash on hand as well as the remaining non-dilutive CIRM and IIA grants amounts to about $5.9M

Research and development expenses, net, for the three months ended September 30, 2019 were $4.01M, contrast to $1.98M, net for the three months ended September 30, 2018.

Not Including participation from IIA and CIRM under the grants and proceeds received under the Hospital Exemption regulatory pathway, research and development expenses increased by $1.59M from $4.07M in the third quarter of 2018 to $5.66M in the third quarter of 2019

General and administrative expenses for the three months ended September 30, 2019 were $1.54M, contrast to $1.26M in the three months ended September 2018.

Net loss for the three months ended September 2019 was $5.6M, or ($0.25) per share, as contrast to a net loss of $3.18M, or ($0.15) per share for the three months ended September 30, 2018.

The USA based company Brainstorm Cell Therapeutics Inc. moved with change of -1.19% to $4.14 with the total traded volume of 73143 shares in recent session versus to an average volume of 108.37K. BCLI’s shares are at 7.81% for the quarter and driving a 17.61% return over the course of the past year and is now at -3.27% since this point in 2018. The average volatility for the week and month was at 2.54% and 2.99% respectively.


Vivian Moore

Vivian Moore – Health and Biotech I am Vivian Moore, I have done my bachelor’s in English literature, and further on I did my master’s in Medicines. My most preferred genre of writing is health and biotech. I have been writing from the past 6 years about articles, web content, and blogs. In my career and education, I like to play along with work. I have also been a teacher in the past for 2 years. I use to teach business and technical writing in a very famous university. However, most recently I am working as an instructor, designer, and training writer. I enjoy socializing a lot. I am a very big extrovert when it comes to nature. A part of all this I enjoy exploring the world and traveling makes me happy.

Leave a Reply

Your email address will not be published. Required fields are marked *